Yusuf Yazici, MD, discussed the effect of the intra-articular inhibitor treatment, lorecivivint, on patient-reported outcomes in patients with knee osteoarthritis.
Many patients who are eligible for total knee replacement do not have the procedure within two years.
In addition to a panel of experts, for the first time, the guideline was developed with the help of patients, emphasizing the importance of shared decision-making.
Investigators assessed sex differences in interleukin-6 response after exposure to acute pain among patients with knee osteoarthritis who were scheduled for total knee arthroplasty.
A novel cathepsin K inhibitor, MIV-711, is no more effective than placebo for reducing pain in patients with symptomatic, radiographic knee osteoarthritis.
Researchers assessed and compared the effectiveness of neurodynamic mobilization techniques with passive robotic physiologic movement for patients with hand osteoarthritis.
Fidia Pharma USA has announced the launch of Triluron (sodium hyaluronate), a hyaluronic acid (HA) based intra-articular viscosupplement.
Data from a study investigating the efficacy and safety of 6-week low-dose prednisolone in patients with painful hand osteoarthritis were presented at the 2019 ACR Annual Meeting.
A hospital-based cohort study found sex heterogeneity in the severity of osteoarthritis symptoms in type 2 diabetes, and an association between insulin treatment and pain severity in men.
Opioids offer minor pain relief and functional benefits in patients with osteoarthritis (OA), with smaller benefits regarding pain for strong versus weak opioids.
